TFII.TO -1.7C 0.13MU -51.63CRWD 5.64PANW 6.15SNOW -4.82V -0.14MAL.TO -0.14
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.01
+0.10 (0.40%)
as of Jul 31, 2026, 8:00:00 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 2, 2026, 12:00 am

This summary was created by AI, based on 23 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing challenges following its pandemic-driven peak during which it surged due to COVID-19 vaccine sales. Experts have pointed out a lack of earnings momentum and concerns over a patent cliff, as key drugs have come off patent and the company needs to innovate to develop new blockbuster drugs. Despite these challenges, many analysts emphasize the attractive dividend yield, which remains around 6-8%. The company is pivoting towards growth areas such as obesity and oncology, and while there's a general belief that PFE is under pressure, patience from investors could yield positive results. Several insights indicate that while it may not attract immediate growth, the company’s efforts in acquisitions and drug development could eventually pay off, given time.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
WEAK BUY

Pfizer Inc(PFE)

Oct 04, 2021
The performance has been disappointing. The problem with big, old pharma is that it is not enough to move the needle. He thinks it is a good one to put away. They are a little constrained on the new product side. He'd suggest an ETF of biotech companies.
Photo of John ZechnerJohn ZechnerUnlock Rating
$42.42

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 30, 2021
Great dividend yield, not trading at a high multiple. Not a pure play. Covid vaccine issue will continue for years to come. Likes healthcare, but it tends to come up as a US political issue. A great story here. He owns JNJ instead.
Photo of Paul Harris, CFAPaul Harris, CFA
No
Unlock Rating
$43.44

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Sep 22, 2021
Good quality stock that won't hurt you. Reasonable valuation, nice dividend. Bad news is everything is already built into the stock. Where's the growth past 2023? Not much upside. He'd add at $32-36, but not here at $44.
Photo of Greg NewmanGreg NewmanUnlock Rating
$44.27

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 17, 2021
A broad company with many types of drugs. Laws in the US stipulates that after spending millions of dollar for franchises, the drug will go off patent in time. Pharmaceuticals have been doing this for a long time.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$43.89

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 13, 2021
It looks good it will get FDA approval for a Covid vaccine for children. Any good news here will help PFE. He's owned this for a while. The current pullback is a buying opportunity.
Photo of Andrew PyleAndrew Pyle
Owned
Unlock Rating
$44.35

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 01, 2021

Many reasons to like this including booster shots which will help shares (though Moderna will benefit more). This has pulled back a but, she likes it here. Has value.

Photo of Karen FinermanKaren FinermanUnlock Rating
$46.04

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Aug 20, 2021
The New York Times reports that the FDA will give full approval to Pfizer's Covid vaccine (for booster shots). He wouldn't rush in after-hours to buy Pfizer, because he's wary of such after-hours moves. Such trading is thin, low-volume.
Photo of Brian KellyBrian KellyUnlock Rating
$48.72

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 18, 2021
It's been on a hot run. The Delta variant gives them a huge tailwind, because Washington is about to mandate Covid booster shots. Pfizer needs it, because they're about to lose the patents on some of their major drugs. Annual booster shots would give Pfizer a giant revenue stream. Shares are up 22% in the past month.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$49.31

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Pfizer Inc(PFE)

Aug 17, 2021
(A Top Pick Sep 24/20, Up 39%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with PFE is progressing well. We now recommend trailing up the stop (from $33) to $42. If triggered this would all but guarantee a investment return over 17%, when including the previous recommendation to cover half.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$49.95

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 16, 2021
Likes it under $40-$36. A bit overbought right now. A good value play and dividend player but would not chase it here. There is probably limited upside here.
Photo of Larry Berman CFA, CMT, CTALarry Berman CFA, CMT, CTA
No
Unlock Rating
$48.77

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 14, 2021

Opportunity for Pfizer and J&J are solid. You give up some appreciation when you select a stock with higher yield. However, total return is the most important. There is more diversification with JNJ with medical supplies. Pfizer's partnership with BioNtech is positive. There is renewed chatter about drug price controls. Both offer good prospective.

Photo of JoAnne FeeneyJoAnne FeeneyUnlock Rating
$40.08

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
WAIT

Pfizer Inc(PFE)

Apr 30, 2021

They report Tuesday. Despite a successful Covid drug, the stock has done nothing because they have a slew of patents about to expire. That said, it's a fine stock with good managers and a safe dividend yield. You could do a lot worse. You would wait before the report.

Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$38.65

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 22, 2021

Not overly bullish on healthcare as a whole, as its growth may be less attractive. Likes medical devices, with a built-in backlog due to Covid. He owns SYK. There should be a significant pickup in procedures over the next 2 years. SYK has strong earnings growth, near a 1-year high. Also look at IHI, the medical devices ETF, packed with companies leading the healthcare sector.

Photo of David BurrowsDavid Burrows
No
Unlock Rating
$38.69

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 13, 2021
Their vaccine has been a boon to their revenues, which jumped 30% in a one year, but this is likely a round trip. Also, margins on this vaccine are fairly low. The vaccine offers some benefit to PFE, but it's limited. Look elsewhere.
Photo of Gordon ReidGordon ReidUnlock Rating
$37.11

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
PARTIAL BUY

Pfizer Inc(PFE)

Apr 09, 2021
Price momentum and valuation has not lined up. It is a low volatility stock with good yield. Almost a bond replacement from the stable and reasonably priced business. Not the cheapest on EBITDA, cashflow or book value. Solid balance sheet.
Photo of Jason MannJason Mann
Owned
Unlock Rating
$36.60

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
Showing 166 to 180 of 885 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EOG 3.18$148.69
SLB 0.68$49.59
SHEL 1.47$91.98
AAPL -24.52$308.91
AMZN 36.08$271.58

Today's Top Picks

TFII.TO -1.7$13.38
C 0.13$132.45
MU -51.63$823.03
CRWD 5.64$190.86
PANW 6.15$331.83

Popular Articles

Latest Sell Signals

AAPL -24.52$308.91
AAPL -24.52$308.91
AAPL -24.52$308.91
T.TO -1.7$13.38
CCA.TO -1.1$59.1

Most Recent Experts

Amy Raskin, CIO, Chevy Chase Trust

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Brianne Gardner

Brianne Gardner

Raymond James

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like